Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. University Hospital of Groningen, Groningen, Netherlands

Survival: ?
Toxicity Grade: 3
Treatments: Chemotherapy
Drugs: Paraplatin
Country: Netherlands
City/State/Province: Groningen
Hospital: University Hospital of Groningen
Journal: Link
Date: 4/2005

Patients: This Phase II study involved 90 women with advanced ovarian cancer. The patients were randomly placed into two groups. Group A (45 patients) had a median age of 60. None of the patients had received first-line chemotherapy before the study.

Treatment: For Group A, the treatment consisted of two chemotherapeutic agents: paclitaxel and carboplatin.

Toxicity: For Group A, grade 3-4 toxicities included: leukopenia, thrombocytopenia, anemia, and neurotoxicity.

Results: Although the median survival for the entire patient population was not determined, the median progression-free survival was 16 months for group A. The authors concluded that the addition of amifostine to paclitaxel-carboplatin therapy "shows only minor but significant activity in diminishing neurotoxicity without preventing paclitaxel + carboplatin-induced bone marrow toxicity."

Support: Bristol-Myers Squibb and Schering-Plough provided financial support for this study. Bristol-Myers Squibb manufactures and markets paclitaxel and carboplatin. Schering-Plough manufactures and markets amifostine.

Correspondence: P.H.B. Willemse, MD

E-mail to a Friend Email Physician More Information